TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02251821

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo allogeneic hematopoietic stem cell transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo umbilical cord blood transplant
Study: NCT05005624

Intervention type: OTHER
Intervention: ADL performance
Description: All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc

Intervention type: OTHER
Intervention: ADL performance
Description: All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc

Intervention type: OTHER
Intervention: ADL performance
Description: All validation groups address the following ten ADL tasks in 9 different combinations of light temperature (in Kelvins - K) and light intensity (in foot candles - fc) in order possible differences to be revealed among the validation groups and light combinations:~1. Phone Book Search (PBS), 2. Supermarket receipt (SupRe), 3. Book reading (BR), 4. Cellular message (CM), 5. Cellular entry search (CES), 6. Reading computer screen (RCS), 7. Drops bottle reading (DR), 8. Subtitles reading (SubRe), 9. Open door test (ODT), and, 10. Screwdriver test (ST).~The 9 light combinations are the following:~3000 K - 25 fc, 3000 K - 50 fc, 3000 K - 75 fc 4000 K - 25 fc, 4000 K - 50 fc, 4000 K - 75 fc 6000 K - 25 fc, 6000 K - 50 fc, 6000 K - 75 fc
Study: NCT02571764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Oats Cookie
Study: NCT03746639

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy modalities
Description: The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 .

Intervention type: OTHER
Group type: OTHER
Intervention: physiotherapy modalities
Description: The physiotherapy modalities will be applied for five sessions a week for 3 weeks.~The all patients will be treated with superficial heating (the moist heat pack will be applied to the patient's lower back for 20 minutes) , transcutaneous electrical nerve stimulation(frequency of 100 Hz, pulse duration of 100 μs, sensory-level amplitude was applied for 25 minutes) , exercise therapy (consisting of flexion, extension, stretching, mobilisation, and postural exercises performed for approximately 25 minutes ) .~In addition to these therapies, continuous therapeutic ultrasound treatment will be applied to patients in first group for 10 minutes; frequency of 1 megahertz, intensity of 1.5 W/cm2, effective irradiation area of the transducer head 5 cm2 .
Study: NCT01801111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered at a dose of 100 mg via tablet, orally, once daily in combination with alectinib to participants who progressed on alectinib alone treatment as per treating physician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib will be administered at a dose of 600 milligrams (mg) via capsule, orally, twice daily.
Study: NCT03313778

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SoC Treatment
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SoC Treatment
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SoC Treatment
Description: Intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SoC Treatment
Description: Intravenous infusion
Study: NCT01174108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi CD34 Reagent System
Description: The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich specific cell populations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor derived G-CSF mobilized PBC
Description: Cell Therapy
Study: NCT04284826

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic injection of Mitomycin-C on bougie-dilated refractory benign esophageal stricture
Study: NCT03189355

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: * D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube~* D4 zonulin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance vector analysis
Description: * D1~* D4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscular echography
Description: * D1~* D4
Study: NCT01545141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemokin Modulatory Regimen (5 MU/m2)
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemokin Modulatory Regimen (10 MU/m2)
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemokin Modulatory Regimen (20 MU/m2)
Description: Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery
Study: NCT04501055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: perineal nerve block
Description: An anesthesia method to block perineal nerve

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: periprostatic block
Description: An anesthesia method to block periprostate
Study: NCT00769262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative weaning
Description: Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Weaning
Description: Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
Study: NCT03598894

Intervention type: OTHER
Intervention: Ambulatory blood pressure measurements
Description: Blood pressure will be assessed with ambulatory blood pressure measurements over the course of a day to discern day/night differences
Study: NCT03485794

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03852823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.
Study: NCT04183725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduning injection
Description: Reduning injection:~2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.~Oseltamivir phosphate granules simulants:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir phosphate granules
Description: Oseltamivir phosphate granules:~Weight≤15kg,30mg,po,bid\*5; 15\<Weight≤23kg,45mg,po,bid\*5; 23\<Weight≤40kg,60mg,po,bid\*5; Weight\>40kg,75mg,po,bid\*5.~+Reduning injection simulants: 2≤Age≤5,0.5ml/kg/day,\<10ml/day+5％GS/0.9％NS 50～100ml,iv drip 30～40gtt/min qd\*5; 6≤Age≤10,10ml/day+5％GS/0.9％NS 100～200ml,iv drip 30～60gtt/min qd\*5; 11≤Age≤13,15ml/day+5％GS/0.9％NS 200～250ml,iv drip 30～60gtt/min qd\*5; Age=14,20ml/day+5％GS/0.9％NS 250ml,iv drip 30～60gtt/min qd\*5.
Study: NCT01475344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Fibrinogen Concentrate
Description: intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion over 5 min/vial:~Body Weight: \< 30 kg / 30-60 kg / 60 - 90 kg / \> 90 kg~No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)~Placebo: 1.5 g / 3 g / 4.5 g / 6 g~Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
Study: NCT04961697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hospital diaries
Description: Diaries will be used by family members, PICU staff or even the patient himself. They will take daily notes expressing feelings and thoughts and describing events that might help chronologically to better understand the course of disease and PICU stay. Photographs and other important PICU memories may also be used in the diary.
Study: NCT03122392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMS 800
Description: AMS 800 Artificial Urinary Sphincter
Study: NCT03810456

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Cognitive Behavior Therapy (iCBT)
Description: Participants randomized to iCBT will receive 16 hours of cognitive behavioral therapy for anxiety over one weekend. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cognitive Behavior Therapy (sCBT)
Description: Participants randomized to sCBT will receive 16 hours of cognitive behavioral therapy for anxiety weekly over a period of 12 weeks. The treatment entails psychoeducation, cognitive restructuring and exposure exercises.
Study: NCT01296139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2\*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
Study: NCT01599169

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)
Description: 2 tablets/day after breakfast during 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: B-Back® placebo (without active compounds)
Description: 2 tablets/day after breakfast during 12 weeks
Study: NCT00428480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily reinforcement of walking speed (DRS)
Description: Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No reinforcement of walking speed (NRS)
Description: Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
Study: NCT02798107

Intervention type: DRUG
Intervention: idarucizumab
Description: drug
Study: NCT00433433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD q4 weeks
Description: Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD q4 weeks
Description: Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABVD q4 weeks
Description: Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD q4 weeks
Description: Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP escalated q3 weeks
Description: Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes\>1.0x109/l

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEACOPP escalated q3 weeks
Description: Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes\>1.0x109/l

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IN-RT 30 Gy (+ boost 6 Gy residual)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IN-RT 30 Gy (+ boost 6 Gy residual)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IN-RT 30 Gy (+ boost 6 Gy residual)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IN-RT 30 Gy (+ boost 6 Gy residual)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET scan
Study: NCT03677869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular gas (C3F8)
Description: Intraocular gas (C3F8) injection
Study: NCT00933504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Treatment duration: 6 weeks.
Study: NCT01844817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OGX-427
Description: Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
Study: NCT02759094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with RefluxStop
Description: A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
Study: NCT04851366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE+ (with add-on modules)
Description: The modules will mainly consist in therapy sessions to provide the adolescents with tools to confront risk situations such as communication skills, coping skills to manage stress, etc. The group will include education about discussing thoughts, feelings, and behaviour as parts of emotion, and emphasis on providing support around the specific risks factors detected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROCARE (UP-A for selective purposes)
Description: This core intervention is meant to respond to the heterogeneity inherent in emotional difficulties presentation by extinguishing distress associated with the presentation of heightened negative emotion in general and reduction or elimination of resultant emotionally-driven behaviours, including avoidance, escape, aggression, and controlling behaviours (e.g., reassurance seeking) that reinforce emotional distress intensity over time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition
Description: Psychoeducation about many different emotions, emphasis on discussing thoughts, feelings, and behavior as parts of emotion, and emphasis on providing support around generally distressing events.
Study: NCT04609423

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod liver oil
Description: 5 ml of cod liver oil as a source of 10 ug of vitamin D and 1.2 g of long-chained n-3 polyunsaturated fatty acids (DHA 0,6g and EPA 0,4g) per day for 6 months x 1 time/day together with the first meal of the day. 5ml of Cod liver oil also contains 250ug vitamin A and 10 mg vitamin E.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil (placebo)
Description: 5 ml of corn oil per day for 6 months x 1 time/day together with the first meal of the day
Study: NCT00832988

Intervention type: OTHER
Intervention: VentricularAutoCaptureTM & ACapTM Confirm
Description: The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.